RN7SL22P

Across TCGA pan-cancer cohorts, RN7SL22P RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RN7SL22P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RN7SL22P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RN7SL22P expression acts as an unfavorable survival marker, although some lineages such as LAML and STAD show a favorable association.

CHOL, UVM, and DLBC are the cancer types where RN7SL22P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	All	0.105	0.536	<.001	123	view →
UVM	OS	Tertile	All	0.104	0.858	<.001	99	view →
DLBC	DFS	Tertile	IV	0.120	0.683	.001	36	view →
LUSC	OS	Tertile	II,III,IV	0.185	0.430	.015	30	view →
KIRC	DFS	Median	III,IV	0.350	0.576	.011	21	view →
LUAD	OS	Tertile	All	0.106	0.392	.003	18	view →
LAML	DFS	Tertile	All	0.780	0.501	.024	18	view →
KICH	OS	Tertile	All	0.648	0.972	.012	12	view →
PAAD	OS	Tertile	All	0.419	0.618	.026	9	view →
STAD	OS	Tertile	III,IV	0.645	0.377	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

RN7SL22P–CHOL (DFS)

Open the CHOL breakdown →